The global flow cytometry market is expected to reach USD 4.79 Billion by 2022 from USD 3.29 Billion in 2017, growing at a CAGR of 7.8% during 2017-2022. Factors such as the attributed to factors such as the continuous technological advancements in the field of flow cytometry, increasing incidence and prevalence of target diseases (such as HIV/AIDS and cancer), growing adoption of flow cytometry in advanced research activities and clinical trials, and increasing availability of novel application-specific flow cytometry products are driving the growth of the global market.
By technology, the global flow cytometry market is categorized into cell-based and bead-based flow cytometry. The bead-based technology segment is expected to grow at the highest CAGR during the forecast period, owing to the procedural advantages offered by this technology over other cell-based technology (enzyme-linked immunosorbent assay (ELISA) and western blot), such as the capacity to detect multiple analytes (also known as multiplexing), high reproducibility, stability, and speed.

On the basis of product and service, the market is categorized into reagents and consumables; instruments; services; software; and accessories. The reagents and consumables segment accounted for the largest share of the flow cytometry market in 2017. Factors such as the development and commercialization of high-quality application-specific reagents and assays and continuous requirement of flow cytometry reagents by end users are expected to drive the growth of the reagents and consumables market in the coming years.

By application, the global market is divided into research, clinical, and industrial applications. The clinical applications segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to the growing usage of flow cytometry in organ transplantation, cancer diagnosis, and hematological disorder treatment.
By end user, the flow cytometry market is categorized into academic and research institutes, hospitals and clinical testing laboratories, and pharmaceutical and biotechnology companies. The hospitals and clinical testing laboratories segment is expected to grow at the highest rate during the forecast period.

Geographically, this market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In 2017, the global market is expected to be dominated by North America, followed by Europe. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period owing to the increasing participation of China, India, Japan, and South Korea in flow cytometry-based research; expansion of research infrastructure; and increasing public-private initiative aimed towards boosting advance research practices in this region.

Flow Cytometry Market

The growth of flow cytometry market mainly restrained by factors such as the high cost of flow cytometry instruments and a dearth of skilled professionals and insufficient knowledge regarding the use of flow cytometers.

Product launches and enhancements are the key growth strategies adopted by major players to strengthen their position in the global market. In addition, strategies such as partnerships and collaborations; acquisitions; and expansions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global flow cytometry market.

As of 2016, BD (US), Beckman Coulter (US), and Thermo Fisher Scientific (US), Merck KGaA (Germany), Sysmex Partec (Germany), Luminex Corporation (US), Miltenyi Biotec (Germany), Bio-Rad Laboratories (US), Sony Biotechnology (US), Agilent Technologies (US), ACEA Biosciences (US), biomérieux (France), Enzo Life Sciences (US), Stratedigm (US), and Apogee Flow Systems (UK), were some of the key players operating in the global flow cytometry market.

The global embolic protection device market is projected to reach USD 604.9 Million by 2023 from USD 405.5 Million in 2018, at a CAGR of 8.3%. Factors such as the rising incidence of cardiovascular and neurovascular diseases, growing funding and investments, launch of technologically advanced embolic protection devices, and rising demand for minimally invasive procedures are expected to drive the growth of the market. On the other hand, product failures and recalls may hinder the overall market growth to a certain extent during the forecast period.
In this report the global embolic protection device market is segmented on the basis of type & material, application, indication, end users and region. On the basis of type, the distal filter devices segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can primarily be attributed to the procedural benefits distal filter devices offer, such as ease of use, enhanced visibility, and crossing profile of the device. On the basis of material, nitinol accounted for the largest share of the market. This segment is also expected to grow at the highest rate in the market. The super-elastic material and braided nitinol design provide full wall apposition and this quality is expected to drive the growth of nitinol in the global market during the forecast period.

On the basis of application, the embolic protection market is segmented into cardiovascular, neurovascular, and peripheral vascular diseases. According to this study, the neurovascular diseases segment is poised to grow at the fastest growth rate in the embolic protection device market. With the increasing target patient population, the demand for embolic protection devices for the treatment of neurovascular diseases is expected to increase during the forecast period.

Based on the indications, the embolic protection devices segment is further segmented into percutaneous coronary intervention, transcatheter aortic valve replacement (TAVR), carotid artery diseases, saphenous vein graft disease, and other indications. The percutaneous coronary intervention segment accounted for the largest share of the global market. The large share of this segment can primarily be attributed to the increasing prevalence of CAD and the rising preference for minimally invasive procedures.

Among end users, hospitals are the fastest growing end-user segment in the embolic protection device market during the forecast period. The market for this segment is mainly driven by factors such as the growing number of angioplasty procedures in hospitals, rising incidence of chronic vascular diseases, favorable reimbursement scenario in developed countries, increasing number of hospitals, and increasing government initiatives to provide quality treatment for cardiovascular diseases.

Embolic Protection Devices Market

Geographically, the embolic protection device market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. In 2017, North America dominated the global market. The rising geriatric population, prevalence of cardiovascular and neurovascular diseases, increasing adoption of minimally invasive techniques, increasing availability of funding, and presence of a large number of medical device product manufacturers are driving the growth of the embolic protection devices market in North America. Asia Pacific, on the other hand, is expected to grow at the highest CAGR during the forecast period due to the growing number of prescriptions for people aged 65 or above, increasing healthcare spending, rising healthcare costs, and increasing target population.

Prominent players in the embolic protection device market are Boston Scientific (US), Medtronic Ireland), Abbott (US), Cordis (A Cardinal Health Company) (US), Allium Medical Solutions (Israel), Contego Medical (US), W.L. Gore & Associates (US), Silk Road Medical (US), Claret Medical (US), and AngioSlide (Israel).

“The global RSV diagnostics market projected to grow at a CAGR of 10.1% during the forecast period”The RSV diagnostics market is expected to reach USD 929.2 million by 2022 from USD 574.3 million in 2017, at a CAGR of 10.1%. Factors driving the growth of this market include rising burden of RSV infections, growing demand for molecular diagnostic tests for the diagnosis of RSV infections, increasing adoption of point-of-care testing for RSV diagnosis and increasing approval of RSV diagnostic kits and assays. On the other hand, the development of RSV vaccine is expected to emerge as a biggest threat which would alter the market growth in the coming years.
“Kits and Assays are estimated to grow at the highest CAGR during the forecast period”
The products market is further segmented into kits and assays, instruments, and other products. The kits and assays segment is expected to account for the largest share and grow at the highest CAGR during the forecast period. Factors driving the growth of this segment include the increasing infection of RSV in newborn infants and young children and growing demand for kits and assays for RSV diagnosis
“The molecular diagnostics segment is estimated to grow at the highest CAGR during the forecast period”
The method market is further segmented into Rapid Antigen Detection Tests, molecular diagnostics, and others methods. The molecular diagnostics segment is expected to account for the largest share of the global RSV diagnostics market in 2017. Market growth can largely be attributed to factors such as the increasing demand for molecular diagnostic testing for RSV diagnosis.
“Asia Pacific is estimated to grow at the highest CAGR during the study period”
Geographically, the RSV diagnostics market is dominated by North America, followed by Europe in 2017. Asia Pacific is estimated to grow at the fastest rate, due to increasing infectious disease burden such as RSV infection, increasing demand for RSV disease diagnosis, and increasing healthcare expenditure in APAC countries.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1–43%, Tier 2–35%, Tier 3–22%
• By Designation: C level–62%, Director level–21%, Others–17%
• By Region: North America–32%, Europe–27%, Asia Pacific–22%, Rest of World –19%

The key players in the RSV diagnostics market include bioMérieux (France), Becton Dickinson (US), Abbott (US), Roche (Switzerland), Danaher (US), Thermo Fisher (US), Luminex (US), BioCartis (Belgium), Hologic (US), and Fast Track Diagnostics (Luxembourg).

Research Coverage:
The report analyses the RSV diagnostics market by product, method, end user, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful.
Key Benefits of Buying the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report can use one or a combination of the below mentioned five strategies for strengthening their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the RSV diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the RSV diagnostics market.
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the RSV diagnostics market.
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various tissue diagnostics products and services across geographies.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the RSV diagnostics market.

“The global defibrillators market projected to grow at a CAGR of 3.1%.”The global defibrillators market is expected to reach USD 10.88 billion by 2022 from USD 9.32 billion in 2017, growing at a CAGR of 3.1%. Factors such as technological advancements in defibrillators, rising prevalence of target diseases, growing focus on providing public-access defibrillators, and training & awareness programs on defibrillators are expected to propel the growth of this market. However, issues related to the use of implantable and automated external defibrillators are expected to restrain the growth of the defibrillators market in the forecast period. The defibrillators market has witnessed significant developments in terms of technological advancements and new product developments. The external defibrillators available in the market have provided numerous benefits to patients in terms of ease-of-use, increased patient comfort, and increased accessibility.

“The external defibrillators segment is expected to grow at the highest CAGR during 2017 to 2022.”
On the basis of products, the defibrillators market is classified into implantable cardioverter defibrillators (ICDs) and external defibrillators. The ICDs product segment is bifurcated into transvenous implantable cardioverter defibrillators (T-ICDs) and subcutaneous implantable cardioverter defibrillators (S-ICDs). The T-ICDs segment is further classified into single-chamber ICDs, dual-chamber ICDs, and cardiac resynchronization therapy defibrillators (CRT-Ds). The external defibrillators segment is further classified into manual external defibrillators, automated external defibrillators (AEDs), and wearable cardioverter defibrillators (WCDs). The external defibrillators segment is expected to grow at the highest CAGR in the forecast period, owing to factors such as the growing focus of key market players on developing easy-to-use defibrillators, increasing support from governments to install AEDs at public places, and rising adoption of WCDs.

“The hospitals, clinics, and cardiac centers segment to dominate the global defibrillators market during the forecast period.”
On the basis of end user, the defibrillators market is segmented into hospitals, clinics, and cardiac centers; pre-hospital care settings; public access markets; alternate care facilities; and home care settings. The hospitals, clinics, and cardiac centers segment is estimated to account for the largest share of the defibrillators market in 2017. Growing number of cardiac implant procedures across the globe and the availability of reimbursements across the developed markets are some of the major factors driving the growth of this segment.

“APAC is projected to witness the highest growth during the forecast period.”
The Asia Pacific defibrillators market is expected to grow at the highest CAGR of from 2017 to 2022. Factors such as the rapidly growing aging population, increasing cases of cardiovascular diseases, improving research infrastructure, and growing focus of key market players to expand their presence in this region are driving the growth of the Asia Pacific defibrillators market.

Breakdown of supply-side primary interviews: by company type, designation, and region:
• By Company Type – Tier 1 –31%, Tier 2 –48% and Tier 3 –21%
• By Designation – C-level – 26%, Director-level – 24%, Others – 50%
• By Region – North America – 29%, Europe – 35%, APAC – 21%, RoW – 15%

The key players in the defibrillators market include Medtronic (Ireland), St. Jude Medical (US), Boston Scientific (US), Koninklijke Philips N.V. (Netherlands), ZOLL Medical (US), BIOTRONIK (Germany), Physio-Control (US), Cardiac Science (US), LivaNova (UK), Nihon Kohden (Japan), SCHILLER (Switzerland), Mindray Medical (China), Mediana (South Korea), METRAX (Germany), and METsis (Turkey).

Research Coverage
This report studies the defibrillators market based on product, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on business strategies adopted by the major players in the defibrillators market. The report analyzes the defibrillators market based on product, end user, and region

• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and product launches in the defibrillators market

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various defibrillators across geographies

• Market Diversification: Exhaustive information about new defibrillator products, untapped geographies, recent developments, and investments in the defibrillators market

• Competitive Assessment: In-depth assessment of market ranking, strategies, and products of leading players in the defibrillators market

“The point-of-care diagnostics market projected to grow at a CAGR of 10.0%.”The global point-of-care diagnostics market is projected to reach USD 38.13 billion by 2022 from USD 23.71 billion in 2017, at a CAGR of 10.0%. High prevalence of infectious diseases in developing countries, increasing incidence of target diseases, and increasing inclination toward home healthcare across the globe are the factors expected to drive the market during the study period. However, the lack of alignment with definitive central lab methods, certain disadvantages of POC testing over central lab methods, and the reluctance among physicians to change existing diagnostic practices are the key factors that are limiting the growth of this market.

“The glucose monitoring products segment is expected to command the largest share of the POC diagnostics market in 2017.”
On the basis of product, the glucose monitoring products segment is expected to command the largest share of the global POC diagnostics market in 2017. The large share of this segment can be attributed to the growing incidence and prevalence of diabetes across the globe and rising preference for home glucose testing.

“The molecular diagnostics segment is expected to be the fastest-growing segment during the forecast period.”
On the basis of platform, the market is segmented into lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. The molecular diagnostics segment is expected to be the fastest-growing segment during the forecast period. Growing advancements in technology and increasing initiatives of market players for developing POC molecular diagnostic products is propelling the demand for molecular diagnostics.

“Asia Pacific is expected grow at the highest CAGR during the forecast period.”
Geographically, the point-of-care diagnostics market is segmented into North America, Europe, Asia Pacific, and RoW. Asia Pacific is expected to register the highest growth rate during the forecast period due to the growing initiatives by market players, increasing patient population base, and rising number of partnerships and joint ventures in this region.

Breakdown of supply-side primary interviews:
• By Company Type – Tier 1 – 35%, Tier 2 – 45% and Tier 3 – 20%
• By Designation – – C level – 15%, Director level – 30%, Others – 55%
• By Region – North America – 45%, Europe – 20%, APAC – 30%, RoW – 5%

The major players of the point-of-care diagnostics market are Abbott (US), Roche (Switzerland), Siemens (Germany), Danaher (US), Becton, Dickinson, and Company (US), Johnson & Johnson (US), Instrumentation Laboratory (US), PTS Diagnostics (US), Quidel (US), Chembio (US), Sekisui Diagnostics (US), Nova (US), EKF Diagnostics (UK), AccuBioTech (China), and Trinity Biotech (US).

Research Coverage

This report studies the point-of-care diagnostics market based on product, platform, mode, end user, and region. The report also studies factors affecting market growth, it analyzes opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends. The report forecasts the revenue of market segments with respect to the four key regions and respective countries.

Reasons to Buy the Report:

From an insights perspective, this research report has focused on various levels of analysis— market ranking analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging segments of the point-of-care diagnostics market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help firms garner greater market shares.